Dasiglucagon is a glucagon analog used to treat severe hypoglycemia in pediatric and adult patients with diabetes. Dasiglucagon is a glucagon analog that acts to increase blood sugar levels.
- Mechanism
- Curator reviewed · 3 references
Dasiglucagon is an analog of glucagon, which is a peptide hormone responsible for increasing blood glucose levels. It has the same mechanism of action as endogenous glucagon by acting as an agonist at glucagon receptors, which are G-coupled receptors expressed throughout the body. Dasiglucagon binds to glucagon receptors in the liver, which activates Gsα and Gq, and consequently, adenylate cyclase. Adenyl cyclase increases intracellular cyclic AMP, which stimulates glycogenolysis and glucogenesis in the liver. As glucose is primarily released from liver glycogen stores, hepatic stores of glycogen are crucial for dasiglucagon to exert its antihypoglycemic effects.
- Primary indication
- Dasiglucagon is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.Curator reviewed · 1 structured indication
- Formula / weight
- C152H222N38O50 · 3382.0 Da (anhydrous, free-base form)
- First approval
- United States, 2021
- Brand names
Resolves to
What you can answer from here — as of August 10, 2026
Which drugs share a target with Dasiglucagon, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account